You are on page 1of 170

:

Increase Inventory In Management And Marketing Planning


In Drugs Store : A case of Kapookya Drugs Udonthani



.. 2551


:
Increase Inventory In Management And Marketing Planning
In Drugs Store : A case of Kapookya Drugs Udonthani

961 493


.. 2551

483210856-5
483210858-1

483210892-1


.




.................................................
( )
...................................................
( .. )


:

.


..




1

, .
: .

:


:
2 1)



2)

5.





400

5%




1
1.1
1.2
1.3
1.4
1.5
1.6
2
2.1 (Check Sheet)
2.2 (Cause and Effect Diagram)
2.3 5.
2.4
2.5
2.6 (General Environment)
2.7 (SWOT Analysis)
2.8 (Five Forces Model) 19
2.9
2.10 (Target marketing STP marketing)
2.11 (Marketing Mix :4Ps)
2.12 (Store design)
2.13
3
3.1
3.2
3.3
3.4
3.5
3.6
3.7

1
3
4
4
4
5
6
7
10
12
12
16
18
21
24
26
28
32
35
35
36
36
37
38
38

( )


4
4.1
4.2
4.3
4.3.1
4.3.2
4.3.3
4.3.4
4.3.5
4.3.6
4.3.7
5
5.1
5.2
5.3


( Check Sheet)




()

39
41
60
60
62
63
66
68
74
76
90
92
93
96
99
102
105
107
110
112
116
118
127

( )


131
133
136
139
142
148
151
158

1 5.
2 7 (6W 1H) 7

3 3
4
5
6 10

EOQ Model53
7 10 EOQ Model
8 10 EOQ Model
9 10
EOQ
10
11
12 .. 2551
13 Five forces Model
14 1
15 1
16 2
17 3
18 3
19

20

21

22
23


11
22
37
41
47
54
55
56
57
59
60
60
63
66
67
67
67
68
68
69
71
73
74

( )

24
25 1
26 2
27 3
28 Check sheet :
29 Check sheet :
30
31
32
33 :
34 :
35 :
36 :
37 :
38 :
39 :
40 :
41 :
42 :
43 :
44
45
46
47 1
.. 2550-2551
48 2
.. 2550-2551
49 1 .. 2550-2551
50 2 .. 2550-2551

83
84
85
87
89
103
104
113
117
119
120
120
120
121
121
121
122
122
123
123
124
125
126
137
138
140
141

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

Check sheet


Five - forces Model

Grid Layout
Racek Layout

1
2
3
:
:
First in First out
FIFO

:
:
:

1
.. 2550-2551
2


3
7
9
15
20
29
29
30
30
40
43
44
45
48
48
49
78
80
81
81
82
93
94
111
137
138
140

( )

28
2


141

1.1

""

58
32 (. 2544:24)








..
2549 .. 3
1 19 / 16
2 I3
3 () 10

3



1.
2.
3.

4.
5.
6.
7.











:

1.2d


1.

2.

3.

4.


1.
2.

3.

1. 5. .

2.
(Stock Card)
3. (First-in First-out)
4.EOQ

1.
2.
3.

4.
5.

1.3
1.3.1
1.3.2
1.3.3
1.3.4
1.3.5 5%

1.4dd
1.4.1
1.4.1.1
1.4.1.2 4
1.4.1.3
1.4.2
1.4.2.1


1.4.2.2


1.4.3
2551 2552

1.5
1.5.1


1.5.2
1.5.3
1.5.4
1.5.5
1.5.6

1.5.7

1.6
1.6.1
1.6.2 6
1.6.3


1.6.4


(http://th.wikipedia.orglwiki/)
1.6.5
( ,2547 : 8)
1.6.6
( , 2542 : 1)
1.6.7

1.6.8

1.6.9

1.6.10



1.6.11 Frist in Frist out ( )
( ,
2550 : 44)
1.6.12


1.6.13



:

2.1(Check Sheet)
2.2 (Cause and Effect Diagram)
2.3 5.
2.4
2.5
2.6 (General Environment)
2.7 SWOT Analysis
2.8 Five Forces Model
2.9
2.10 (Target marketing STP marketing)
2.11 (Marketing Mix :4Ps)
2.12 (Store design)
2.13

2.1 (Check Sheet)


(Check Sheet)
-
-
- (Visual)
- (
, )
-
-
-
-

-
-
-
-
-
- ( . 2547)

Defect

Day
1
////
///

2
3
4
A
/
//
B
//
////
/
C
///
//
2 (Check Sheet) : . 2547,
7
( Check Sheet)

2.2 (Cause and Effect Diagram)


(
Fish Bone
Diagram)
(Ishikawa Diagram) ( Problem)
(Possible Cause)
2.2.1
6
2.2.1.1
2.2.1.2
2.2.1.3
2.2.1.4
2.2.1.5

2.2.1.6
2.2.2


4M 1E (Factors) 4M 1E
M - Man
M - Machine
M - Material
M - Method
E - Environment
4M 1E
( input) 4 P
Place , Procedure, People Policy 4S Surrounding, Supplier, System Skill
MILK Management, Information, Leadership, Knowledge


2.2.3

3 : . 2547,
7

(Problem or Effect) (Causes)

- (Factors) ()
-
-


( Fishbone Diagram)

3 - 6 (Sub-Bone)


4 5


1.

10

2.


1.

2.


2.3 5.
5. (5S) 5


5.
5.


5. 5S 1

11

(SEIRI)

(SEITON)

(SEISO)

(SEIKETSU)

(SHITSUKE)

1 5. : 2547,


1.
2.
3.
4.

1.
2.
5.
5.

12

2.4
3
( . 2547 : 400)
2.4.1 (Generic Name)

Paracetamol USA Acetaminophen 4
2.4.2 (Chemical Name)

Ergotamine tartrate Ergotaman-3',6', 18trione,12'-hydroxy-2'-methyl-5'-(phenyl-methyl),(5'(alpha))-,[R-(R*,R*)] 2 ,3dihydroxybutanedioate(2:1)(tartrate).
2.4.3 (Trade Name)

2.4.3.1
2.4.3.2
2.4.3.3
2.4.3.4
2.4.3.5
2.4.3.6
2.4.3.7
2.4.3.8
2.4.3.9
2.4.3.10
2.4.3.11

2.5
2.5.1 (Inventory Costs) 3
2.5.1.1 ( Carrying /Holding Costs)

13

()

2.5.1.2 ( Ordering Costs)

2.5.1.3 ( Shortage Costs)

2.5.2 ( ,2543 : 252)
2.5.2.1

2.5.2.2
2.5.2.3

2.5.2.4

2.5.2.5

2.5.2.6

2.5.3 (Types of Inventory)
2.5.3.1 ( Raw Material Inventory)


2.5.3.2 ( Work-in-Process : (WIP) Inventory)

(Cycle Time)
2.5.3.3 Maintenance/Repair/Operating :
(MROS)

2.5.3.4 ( Finished Goods Inventory

14

2.5.4 (Inventory Management)




2
2.5.4.1 (Reorder Point)
2.5.4.2 (Economic Order Quantity)
2.5.5EOQ Model (Economic Order Quantity Model)

( Order Point
Policies)

2.5.5.1
2.5.5.2 ( Lead Time)

2.5.5.3 10
2.5.5.4
2.5.5.5 ( Supplier) (Minimizing Costs)

( )

( )
2.5.5.6EOQ Model (Economic Order Quantity Model)
(1)
(2)
(3)
= +
d Total Cost = 0

dQ


(4) 4.5.6.3

Q = (/)
Q* = (/)
D = (/ )
S = (/)

15

H = (// )
W = ()
N = (/ )

1 =

D
S
Q
2 = D H
2

. 1

3 =
D = D
H
S

. 3

. 2

4 (Q*) =
() (N) =

.. 4
. 5

D
Q*

(/) T =

2 DS
H

() (W)
()(N)
T=

w
n

. 6

Reorder Point (ROP)

16

()
Q*
(d) =

()
()


(ROP)
()
L

4 :
. 2543,

(ROP)
= (d) x (Lead Time)

ROP = dL + SS (SS = )



2.6 (General Environment)




( ,2547 : 216-218)
2.6.1 (Demographic)

( ) ( maturity)

17



2.6.2 (Sociocultural)



(
)
(
) (
)
2.6.3 (politice and law)


( )
( SMEs)

2.6.4 (technology)

( GMOs)
internettrading online-trading




2.6.5 (economics)

( local)
( global) ( GNP)

18

2.6.6 (global)


( IMF)

EU (European Union) OPEC (Organization of Petroleum Exporting Countries) ASEAN
(Association of South East Asian Nations)






2.7 SWOT Analysis


SWOT Analysis

Strength ( )
Weakness( )
Opportunity() Threat( ) SWOT
( ,2547 : 116)
2.7.1 (Strength)
4PS
4PS

2.7.2 (Weakness)
4PS

19

2.7.3 (Opportunity)



2.7.4 (Threat )


( ,2547 : 116)
SWOT Analysis

SWOT



2.8 (Five Forces Model)


Five Forces Model Michael E. Potter 5

2.8.1




2.8.2


( Market Share)



2.8.3

20

2.8.4





2.8.5


2.

4.

1.

5.

3.

5 5 Force Model : Five Force Model


Michael E.Potter .2004
Five Force Model

21


Five Force Model

2.9
( Analyzing Consumer Behavior)



6w 1H WHO WHAT
WHERE WHEN WHY WHOM HOW 7 7O Occupants
Objects Objective Organizations Occasions Outlets Operations

22

2 7 (6W 1H) 7
: 2541,
(6W 1H)


1.

(4Ps)
(Who is the target market?)
1.

2.

3.

4.


2.
(What does the consumer buy?)

1.
2.
3.
4.
5.

3.
(Where does the consumer
buy?)

4.

(When does the consumer buy ?)

23

2 ( ) 7 (6W 1H) 7
: 2541,
(6W 1H)


5.

(Who does the consumer buy?)


(Objective) 1.
2.




1.

3.
2.
4.

3.
6.
(Who participates in the buying?)

1.
2.
3.
4.
5.

7.
(How does the consumer buy?)

1.
2.
3.
4.
5.

24

2.10 (Target marketing STP marketing)


2.10.1 (Market Segmenting)
2.10.2 (Market Targeting)
2.10.3 (Market Positioning)
2.10.1 (Market Segmenting Segmenting) ( ,2550:39)



2.10.1.1 ( Geographic Segmenting)


2.10.1.2 ( Demographic Segmenting)

2.10.1.3 ( Phychographic Segmenting)



2.10.1.4 ( Behavioristic Segmenting)

2.10.2 (Market targeting)

2
2.10.2.1 3

(1)
(2)
(3)

25

(4) 3
2.10.2.2 ( Undifferentiated marketing)

(1) ( Differentiated marketing)

(2) (
Concentrated
marketing)

2.10.3 (Market Positioning)


(Positioning)
(
2548: 54-55)






7
(1) ( Positioning by
Product Attributes and Benefits)

(2)/ (Positioning by Price/Quality)




/

(3) ( Positioning by Use or Application)
/

26

(4) ( Positioning by Product


Class)
MP3

(5) ( Positioning by Product Use)

(6) ( Positioning by Competitor)


(7) ( Positioning by Cultural
Symbols)

( . 2548: 55-58)


2.11 (Marketing Mix :4Ps)


(Marketing)

(Marketing Mix : 4Ps)


( . 2546 : 42)
2.11.1 (Product) ( Value)
( Value)


( Goods) ( Services)
( Idea) ( Philosophies)
(Lessons) (Concepts) (Advice)
2.11.2 (Price)


27



2.11.3 (Place)



2.11.4 ( Promotion)


(Promotion mix or Communication)
2.11.4.1 (Advertising)

2.11.4.2 (Personal Selling)

2.11.4.3 (Sales Promotion)



3
(1)
(Consumer Promotion)
(2) ( Trade
Promotion)
(3) (Sales
Force Promotion)
2.11.4.4 ( Publicity and Public Relations)



2.11.4.5 ( Direct Marketing)
( Response)

( . 2541 : 3536)
4

28

2.12 (Store design)


2.12.1 (Store layout) ( . 2546)

2.12.1.1 (Convenience)


2.12.1.2
2.12.1.3
2.12.1.4

2.12.1.5

2.12.1.6
2.12.1.7
2.12.2 ( , 2536)







29

7

2.12.3
2.12.3.1 (Grid layout)


( ,2546)

30

8 (Grid layout)
2.12.3.2 (Racetrack layout)


(Impulse purchasing) ( ,2546)

9 (Racetrack layout)

31

2.12.3.3 (Free-form layout)


(Boutique layout)



( )

( ,2546)
2.12.4
2.12.4.1


(
,2536 : 34-46)
2.12.4.2

( ,2536 : 34-46)
2.12.5 ( . 2546)
2.12.5.1 ( Idea-oriented presentation)

2.12.5.2 (Style/item presentation)


2.12.5.3 ( Color presentation)

2.12.5.4 (Price lining)

2.12.5.5 ( Vertical merchandising)

2.12.5.6 ( Tonnage merchandising)


32

2.12.5.7 ( Frontage presentation)




2.12.5.8 (Fixtures)






2.12
(2539)
2 ( 8.00-16.00 .)
1 ( 16.30-21.00 .)
2 6 3





(2539)


3



(2541)
24,000

33

On Hand An FS : 011
A




( 2543)



50%

Ishikawa Diagram

51.6% 269,401.22
20% .. 2543
3,625,515.40 69%
.. 2543
(2544)
.. 2517
23




SWOT Analysis
10%

(2546) SIKKENS



1.

34

2. Premium Premium

3.
-
4.
5.

6.
7.
(2550)


35


:
3.1.
3.2
3.3.
3.4.
3.5.
3.6.
3.7.

3.1

:
142,112 ( . 2551 )

3.2

:
142,112 ( , 2551 )
Taro Yamane (1967)

N
n =
1 N E

n =
N =
E =
95 % 0.05

36

N =

142,112
2
1 142,1120.05

= 398.88 400


Yamane 142,112 95 % 5 %
400
(Multistage Sampling)

1 (Judgement or Purposive
Sampling)
2 (Quota sampling)
400 1
140 2 185 3 75
3 (Convenience) Non-probability

3.3
2
3.3.1
- 1 19/16
- 2 3I
- 3
10
3.3.2

3.4

3.4.1 (Check Sheet)

3.4.2

37

3.4.2.1



3.4.2.2

(1)

(2)

(3)

3.5
3.5.1 (Primary Data)
(Quota sampling)
() 400
5 15
20
3.5.1.1

15 - 20 2551 5 12 .00 -20.00 .
Yamane 400
3
3 3

:
1 3
200
2
200

400
3 1 3
200 1 3 500
2

38

200 2

3.5.1.2
3.5.1.3
3.5.2 (Secondary Data)

3.6

400 3
1
2
3

3.7

(Frequency) SPSS
( Percentage)

39

4.1
( )
( )

1.
2.
3.
4.

5.
6.
7. ( 6 )
8.
9.
10.
11.
12.

. 2551 1
2 1 19,673 0.77 % 2
2 1 18,836 0.4 % 3
.. 2551

40

(Ishikawa Diagram)


10
10
4.1.1




4.1.2

41

4.2


4.2.1


4 : 5 .

()
1
2.55
2
2.30
3
2.45
4
2.35
5
2.40

2.41
4.2.1.1
5. 2.41
4.2.1.2

(Shortage Cost or stock out Cost)

4.2.1.3 -

4.2.1.4

42

4.2.2

4.2.2.1 5.
:
-
-
: 1 - 5 2551
: 5.
1
3




1.
2

.
2.1
2.2
2.3
2.4
2.5
2.6
2.7
2.8
2.9
2.10
2.11

43

, ,

2

3 4,000
/
Microsoft Excel


11 1

11 1


10

44


(Promotion Area) (Free zone)




12 2
12

45


( Vertical merchandising)

2


10

(Promotion Area)

, ,

13 3

46

13
1

10

(Promotion Area)
(Free zone)

(Vertical merchandising)


3







2



3



4
3 .

5
4.

47

1.
2.
3.
4.
5.
6.
7.

1
2
3
4

:

4,000
5.
2.41 1 2 1.15
5.

4.2.2.2 FIFO (First in First out)
:
-
- -
: 1 2551 31 2552
:
(Stock card)
(First in First out)

1. ()

48

1

(STOCK CARD)
:

1
2
3
4
5
6
7

//
( )
25/11/51
18/11/51
10/11/51
7/11/51
22/11/51
3/11/51
30/11/51


_0001
_0004
_0003
_0002
_0005
_0001
_0001

Amexicillin 500 mg.


Coamox 250
Betnovate N 5g.
Bethasone 5g.
Doxycycline 100 mg.
Amexicillin 500 mg.
Amexicillin 500 mg.

()
40
17
15
21
25
3
10

//
()

()

29//12/13
04/06/11
16/12/13
15/09/12
05/09/12
29//12/13
29//12/13

14 (STOCK CARD) :
2. // ()
-
1

(STOCK CARD)
:

1
2
3
4
5
6
7

//
( )
3/11/51
7/11/51
10/11/51
18/11/51
22/11/51
25/11/51
30/11/51


_0001
_0002
_0003
_0004
_0005
_0001
_0001

Amexicillin 500 mg.


Bethasone 5g.
Betnovate N 5g.
Coamox 250
Doxycycline 100 mg.
Amexicillin 500 mg.
Amexicillin 500 mg.

()
40
21
15
17
25
3
10

//
()

()

29//12/13
15/09/12
16/12/13
04/06/11
05/09/12
29//12/13
29//12/13

15 : FIFO (First in First out)

49

15

3/11/51 Amexicillin 500 mg. _0001 40


25/11/51 Amexicillin 500 mg. _0001 3
30/11/51 Amexicillin 500 mg. _0001 10
3.




Amexicillin 500 Amexicillin 500
Amexicillin 500

16

1
2
3

//
( )
3/11/51
25/11/51
30/11/51


_0001
_0001
_0001

Amexicillin 500 mg.


Amexicillin 500 mg.
Amexicillin 500 mg.

()
40
3
10

Amexicillin 500 mg. 30


Amexicillin 500 mg.
3/11/51

16 FIFO (First in First out)


: 60 ( -)
:
-

-



4.2.2.3 ( EOQ Model )
:
-
-
-

50

: 15 25 2551
:



- Microsoft Excle
-
EOQ Mode

EOQ Model

Q* = 2 DS
H

Q* =
D = (/)
S = (/)
H = (// )

1. (S)
2.(H)
3.
4. 3
10
10

1. Amexicillin 500 mg.
275 /
2. 216 /
3.
252 /
4. 21
160 /
5. 28
160 /
6.
300 /
7. 35 21
154 /
8. ()
758 /
9.
240 /
10. kanolone
250 /

51


Amexicillin 500 mg.
(Ordering Cost : S)
1 4

7

4 x 7 = 28
3
70 %

= 10,000 3 0.70
47

= 750 //

10 //
15 //
= 750 + 10 + 15
= 775 //
(Holding Cost : H)
1. (4.25%,
)
Amexicillin 500 = 275 0.0425
= 11.69
2.
600,000
20 30,000 27


=

Amexicillin 500 0.40

= 0.40 30,000
27

= 444.44 /5

88.89 /
3. 3 3


10,000
120,000 /

52



10,000
120,000 /


10,000
120,000 /

360,000 /
2,700 1 2551
3 360,000 = 133.33 /
2,700

4. 2,000 / /
24,000 /
24,000 = 16 //
2,700

= + ++

Amexicillin 500 mg.
= 11.69 + 88.89+133.33+16
= 249.91 //


Amexicillin 500 mg. 275 / 1
30
EOQ Model
Amexicillin 500 mg.
= ( + ) +
= HO DS +
2

H = 161.91 //
Q
=
/
/
30
=
6

D
S

=
=
=

5
/
30

775 //

53

Amexicillin 500 mg.


249.91 5 30 775
=

30 275

=
=

624.78+4,650+8,250
13,524.78

EOQ Model
Amexicillin 500 mg.
= ( + ) +
(EOQ)
EOQ (Q*) = 2 DS
H

Q* =

2 30 775
249.91

Q* = 13.64 /

H = 249.91 /
Q* = 13.64 /
D = 30
S = 775 /
Amexicillin 500
= 249.9113.64 30 775 30 275

13.64

= 1,704.39+1,704.55+8,250
= 11,658.94
() (N) = D = 30 = 2.22 3 /
Q*

13.64

(/) T
=
()
()
= 365
3

121.67 = 122

54

(ROP)
ROP = /(d) (L)
Amexicillin 500 mg. = 10 (
)
/
= 30
365

= 0.08 /

= 10 0.08
= 0.8
1
Amexicillin 500 mg.
= 13,524.78 -11,658.94
= 1,865.84 1,866 /
6 10 EOQ Model




()
( / )
(/ )
()
1. Amexicillin 500 mg.
0.40
30
6
10
2.
0.60
65
12
10
3.
0.60
60
10
10
4. 21
0.20
70
12
10
5. 28
0.20
65
12
10
6.
0.60
60
8
10
7. 35 21
0.20
68
12
10
8. ()
0.40
40
7
10
9.
0.20
72
9
10
10. kanolone
0.20
60
10
10


( /)
0.8
0.18
0.16
0.19
0.18
0.16
0.19
0.11
0.20
0.16

55

7 10 EOQ Model

D
S
H
Q

QH/2
DS/Q
/
30
775 249.91
5
6
624.78
4,650

()

EOQ
(Q*)

8,250

13,524.78

13.64

65

775

825.18

5.42

12

2,236

9,243.12

14,040

25,519.36

7.81

60

775

826.71

10

2480.13

7,750

15,120

25,350.13

7.50

4.
21
5.
28
6.

70

775

378.35

5.83

12

1.102.89

9,305.32

11,200

21,608.21

8.10

65

775

378.35

5.42

12

1,025.33

9,294.28

10,400

20,719.61

11.54

60

775

828.75

7.5

3,100.31

6,200

18,000

27,300.31

7.49

7. 35
21
8. ()

68

775

378.10

5.67

12

1,071.91

9,294.33

10,472

20,838.24

11.81

40

775

625.99

5.71

1,787.20

5,429.07

30,320

37,536.27

7.04

9.

10.
kanolone

72

775

381.75

1,527

6,975

17,280

25,782

12.09

60

775

382.18

10

1,146

7,750

15,000

23,896.54

11.03

1. Amexicillin
500 mg.
2.

3.

Q (/)
Q* (/)
D (/ )
S (/)
H (// )
D , EOQ

242,075.45

56

8 10 EOQ Model

D
S
H
Q*

Q*H/2
DS/Q*
/
30
775 249.91 13.64
3
1,704.39 1,704.55

()

ROP
( )

8,250

11,658.94

65

775

825.18

11.05

4,559.12

4,558.82

14,040

23,157.94

60

775

826.71

10.60

4,381.56

4,386.79

15,120

23,888.35

4.
21
5.
28
6.

70

775

378.35

16.93

3,202.73

3,204.37

11,200

17,607.10

65

775

378.35

16.32

3,087.34

3,086.70

10,400

16,574.04

60

775

828.75

10.59

4,377.64

4,390.93

18,000

26,768.57

7. 35
21
8. ()

68

775

378.10

16.79

3,157.14

3,115.59

10,472

16,784.83

40

775

625.99

9.95

3,114.30

3,115.58

30,320

36,549.88

9.

10.
kanolone

72

775

381.75

17.10

3,263.96

3,263.16

17,280

23,807.12

60

775

382.18

15.60

2,981

2,980.77

15,000

20,961

1. Amexicillin
500 mg
2.

3.

Q (/)
Q* (/)
D (/ )
S (/)
H (// )
D , EOQ

217,757.77

57

9 10 EOQ

EOQ

EOQ ()

()
()
(ROP: )
1. Amexicillin 500
13,524.78
11,658.94
1,865.84
1
2.
25,519.36
23,157.94
2,361.42
2
3.
25,350.13
23,888.35
1,461.78
2
4. 21
21,608.21
17,607.10
4,001.11
2
5. 28
20,719.61
16,574.04
4,145.57
2
6.
27,300.31
26,768.57
531.74
2
7. 35 21
20,838.24
16,784.83
4,053.41
2
8. ()
37,536.27
36,549.88
986.39
2
9.
25,782
23,807.12
1,974.88
2
10. kanolone
23,896.54
20,961
2,935.54
2

242,075.45
217,757.77
24,317.68
8 10
EOQ

1.Amexicillin 500 mg 14 275
1 10
1,865.84
2. 8 216
2 10
2,361.42
3. 8 252
2 10 1,461.78

4. 21 9 120
2 10
4,001.11

58

5. 28 120 12
2 10
4,145.57
6. 8 300
2 10 531.74
7. 35 21 12 120
2 10
4,053.41
8. () 8 758
2 10 986.39
9. 13 240
2 10
1,974.88
10. kanolone 13 250
2 10
2,935.54
:
:
EOQ Model
10
24,317.68 242,075.45
10

10
EOQ Model


EOQ Model
Q* =

2 DS
H

Q* =
D = (/)
1
S = / 10
775 //

59

H = (// )
10 249.91 //

2 D 775
249.91

10

D
Q* = 2 DS

1.

2 ....... 775
249.91

2.

2 ....... 775
249.91

3.

2 ....... 775
249.91

4.

2 ....... 775
249.91

10

249.91 Q * D 775 ( D )

2
Q *

()

= D
Q*

3.
=


ROP = / X
/
= D
365

= 10
ROP = / X 10

60

1.
2.
3.
4.

11



....
..
..

..
..
....
..
.

..
.....

4.3
1 2


4.3.1 (General Environment Management)
4.3.1.1
142,112 69,506 72,606
2,979 / ( , 2550)
12 .. 2551

0-14
15-29
30-34
165,138
195,280
75,745

156,742
188,197
73,002

321,880
383,477
148,747

: , 2551

35-39
73,710
73,538
147,248

40-59
190,278
196,239
386,517

60
65,110
76,594
141,704

765,261
764,312
1,529,573



4.3.4.2 (Sociocultural)
( 2549) 34,335 (
. 2551) 55 3 (
. 2551)


5

61





4.3.4.3 (Political and law)







.
4.3.4.4 (Technology)

( Bar Code)
(Universal Product Code UPC) ( Laser
Scan)



4.3.4.5 (Economics)

GPP ( 2549) 52,652 - 24.34%
16.08 % 10.36% ( 2549) 34,335 (
)

4.3.4.6 (Global)



62



4.3.2 Five Forces Model

4.3.2.1 (Rivalry Among Current Competitors)




79.5 1
( 1
..)
4.3.2.2 (New Entrants)

92

4.3.2.3 (Threat of Substitute Product or Services)



4.3.2.4 / (Bargaining Power of Suppliers)




4.3.2.5 (Bargaining Power of Customer)




63

13 Five Forces Model

1.

2.

3. /

4.

5.

4.3.3 (SWOT Analysis)



SWOT Analysis

SWOT Analysis : 1
(Strengths)
1. (
)
2.
3.
4. 09.00-23.00.

(Weakness)
1.

2.
3.
(Opportunities)
1.

2.

(Threats)
1. 2

2.
3.

64

SWOT Analysis : 2
(Strengths)
1. ( ,
)
2.
3.
4.
(Weakness)
1. 2 16.00.-23.00 .

2.
3.
(Opportunities)
1.

2.

3.

4.
(Threats)
1.

SWOT Analysis : 3
(Strengths)
1.

2.
3.
4.
(Weakness)
1. 15.30.-22.00.

65

2.

(Opportunities)
1.


2.

3.

(Threats)
1. 3

2.

SWOT Analysis : 3
(Strengths)



(Weakness)



(Opportunities)


(Threats)



4.3.4 (Competitive Situation)

66



:
-
-

..


- ( 500 )
-
-
-
4.3.4.1 : 1

1
14 1


17.00

1

67

15 1


1
4.3.4.2 : 2
2
1
16.00-23.00 .


16 2

16 2
1

2
4.3.4.3 : 3

3

68

17 3


1.

3

18 3


3
4.3.5



400
4.3.5.1
(1)

(2)

(3)

69

4.3.5.2
-
19


1.

()

/./.

/
/

106
294
400
4
281
74
41
400
50
51
287
12
400
231
112
45
12

26.5
73.5
100
1.0
70.3
18.5
10.3
100
12.4
12.8
71.8
3.0
100
57.8
28.0
11.3
3.0

5,000
5,001 10,000
10,001 15,000
15,001

400
151
182
53
14
400

100
37.8
45.5
13.3
3.5
100

2.

18
19 25
26 - 30
30

3.

4.

5.

19
73.5% 26.5%
19-25 , 26-30 30 70.3%, 18.5% 10.3%
, /./.

70

71.8%, 12.8% 12.4%


/ , /
57.8%, 28.0% 11.3%
5,001-10,000 , 5,000
10,001-15,000 45.5%, 37.8% 13.3%

71

-
20

()


1.
253
21

153
13

86
7

51
4

189
16

97
8

53
4

318
27

1,200
100
2.

296
74.0

26
6.5
/
59
14.8

19
4.8

400
100
3.
75
6


234
19

85
7

202
17
/
116
10

128
11

88
7

84
7

188
16

1,200
100
4.
243
60.75


36
9.0

121
30.25

400
100

72

20()

()


5. (/
214
53.5

)
( )
167
41.75

19
4.75

400
100
6.
06.00 09.00 .
20
5.0

09.01 12.00 .
22
5.5
12.01 15.00 .
29
7.3
15.01 18.00 .
151
37.8
18.01 21.00 .
173
43.3
21.01 24.00 .
5
1.3

400
100
7.

394
98.5


6
1.5

400
100
20


27%, 21% 16%

74%, 15% 6%


19%,
17% 16%

60.75%, 30.25% 9%

73



65.5%, 59.8% 17.8%

18.01 - 21.00 . 15.01 - 18.00 . 12.01 - 15.00 . 43.3%, 37.8%
7.3%
98.5%
1.5%
21



1.

2.

3.

()

203
41
143
7
394
104
45
84
126
23
12
394
82
121
48
19
16
88
20
394

51.5
10.4
36.3
1.8
100
26.4
11.4
21.3
32
5.8
3.1
100
20.8
30.7
12.2
4.8
4.1
22.3
5.1
100

74

21

51.5%, 36.3% 10.4%


26.4%, 32% 21.3%


30.7%, 22.3%
20.8%
4.3.6 (Target marketing STP marketing)


4.3.6.1 (Market Segmentation Segmenting)

22

18
19-25
26-30
30

4.3.6.2 (Market Targeting)


(Market target) 3
19-25


2,979 /.. ( : 2551) /

75

57.8% / /
19-25
/
74.0%, 14.8% 6.5%

(1) /

(2) /

(3)


4.3.6.3 (Market positioning)
(Positioning)

(1) ..
(2)
(3)
(4)
4.3.6.4

(1) (Who is the target market?)
- /

- /

-

76

(2) (What does the consumer buy?)



/
(3) (Where does the consumer buy?)


(4) (When does the consumer buy?)


18.00 -21.00 . 15.00-18.00
(5) (Why does the consumer buy?)


(6) (Who participates in the buying)


(7) (How does the consumer buy?)

/

4.3.7



(Vision)

(Mission)
1.
2.
3.
4.
5.
(Objective)

77

5%

2551- 2552

1.

(Target
marketing STP marketing)
- /

- /

-

2.



1

1.
2.

1.

, ,

Free Zone

78

17








(Promotion Area)
(Free zone)




79

2.


:


5.
: 100 ( )
2


10%
1 , ,

1.Blink 60
2.Blackmore Zn 100
3.Q Marin 30
4.Viteen 30
5.Hi Srim 30
6.L.C.H Bioplus 30
7.Peptide Collagen 1000 m.
8.Grutatiole 500 mg. 30
9.Grutatiole 750 mg. 30
10.Vitamin C 1000 mg.

80


Promotion !!
..
500mg 300/
750mg 700/
150/2kg./
100
!!
10%
1
2
3

18



240
38

: 20 ( 240 )
3


( 12-20 ) C
/ /

81

Vitamin C 500mg 150


500mg. 300

!!

450 350
1
2
3 .

19 :
( 21-35 )

-
-

A : 799

500 mg + Vitamin E

B : 899
Peptide Collagen


A+B 10%
1
2
3

20 :

82


-
-
( 36-50 50 )
-
-

Vitamin 150 /

1
2
3

!!!
10%

21 :




100

: 50 ()

83

1. 1,000
3
10-30% 10%
2.
, , , ,

3.

4.
1 1 1 2

1,000
2,000
3,000
4,000

22

1,080 (, )

84

24

..
..
..
()
1 2 3 4 1 2 3 4 1 2 3 4
1
100
2
20
3
50
4
1,080

1,250
: 1

4

2551 104,750 2552


122,618 (104,750 -122,618 ) 17,868

1,250

8,418
1,250
7,168
(..51 - ..52)

17,868
9,450
8,418
1,250
7,168

85


25 1
1

..
()
(%)
2550
99,620

5.2%
2551
104,750
2550
97,512

8.6%
2551
105,875
2551
114,596

7.0%
2552
122,618
2551
5,130 5.2 % , 2551 8 ,363
8.6% 2552
8,022 7%
5 %

86

: 2




2551 138,662 2552
214,342 (138,662 - 214,342) 75 ,680

1,250

25,315
1,250
24,065
(..51 - ..52)

75

,680
50,365
25,315
1,250
24,065

87


26 2

..
2550
2551
2550
2551
2551
2552

2
()
130,154
138,662
164,860
176,400
194,856
214,342

(%)
6.5%
7.0%
10.0%

2551
8,508 6.5 % 2551 11 ,540
7.0 % 2552
19,486 10%
5 %

88

: 3




2551 55,780 2552
69,465 (55,780 - 69,465) 13,685

1,250

25,315
1 ,250
24,065
(..51 - ..52)

13,685
7,942
5,743
1,250
4,493

89


27 3
3

..
()
(%)

2551
55,780

2551
64,679
15.94%

2552
69,465
7.41%
2551
8,899 15.94% 2552
4,786 7.41 %
5 %

90

5.1
3 1
4 2 3 3
3 /










(Check Sheet)
(Fish Bone Diagram)
2

- (SWOT Analysis)
3

- (Five Force Model)




91

5.1.1
5.1.1.1




5.

5.




51.1.2


SWOT
Analysis, Five Force Model
-
400

19-25 5,001-10,000 /

/

18.00-21.00 .


-
18 , 19-25 , 26-30 30
, , /
/


4 1 2

92

3 4

5.2

5.2.1



5.2.2
4


93

5.3
5.3.1
22
23



/



22
22

94




(Microsoft Excel)
/

EOQ

23
23
(
Microsoft
Excel)
EOQ

95

5.3.2
5.3.2.1
(Safty stock = ss)



5.3.2.2 Linear Programming

96

.(2551). 2551. 7 2552.http://www.voanews.com


.(2547). . 13 2552.
http://computer.pcru.ac.th/emodledata/15/week_5.doc
.(2530). . http://www.ocsc.go.th
. , .(2550).
. 13 2552. http://libary.lib.ru.ac.th
. (2541).
.

. (2544).
.
. (2543). .

. (2543). . :

.(2548). 5 2552. http://learners.in.th/file/ibirdboy/FishBone.doc


.(2539). .

. (2546). SIKKENS
.

. (2543). . :

.(2546) . Retailing Management . :


.
.(2552). . 5 2552.
http://www.pharmacycouncil.org/html/htmlexpand/drug_store04.html
.(2550). . 10 2552.
http://www.udonthaniteam.org/
.(2551)..
10 2552. http://www.moc.ac.th/udonthani

97

( )
. (2539). .

. (2547). . 4. :
.
. (2549). . :
. (2544).
. :

98

99

100


.
8 .. 2551 1

1.
3 1 .. 2549 2 .. 2550
3 .. 2551
2.

3.
( . ) 3
1
2 .. 3 ..
4.
1 11.00-23.00. 2 16.00-23.00.
3 15.30-22.00 .
5.

6.

7.





8.

9.


10.

101

11.

12.


13.


14.
30%

15.

16.


17.

102


(Check Sheet)

103

28 (Check Sheet ) :


1.



2.41 (
2.


5 )

3.


4.





5.

6.
12

7.

8. ( 6 )
25

9.


10.

11.

12.

13. ,

14. ,
,

15.

16.
/

104

29 (Check Sheet ) :

1.
5.

2.
1.15 (


5 )

3.


Microsoft Excel

4.
5.



5.


6.
First in First out

7.


8. ( 6 )

9.

10.
EOQ
11.

12.

13. ,

14. ,
,

15.

16.
/

105

106

(Bases of Competition)
1. (Customers-based competition /Customer oriented)



(Who they are : competition for the same budget)
(When they use it)
(Why they use it : benefits sought)
2. (Marketing Activities /Marketing
oriented)



AVON Tupperware

3. (Resource- oriented)


IBM Emerson
Electric


4. (Geographic)


( , 2546 : 6-3)

107

108

(Economic)


15 2551

2


/
( 2549)
1.53


11,730.302 ...

20
2552

GPP (
52,652
2549)
16.08 %
1.

10.36%

24.34%

-
3.98%

45.23%


34,335

( 2549)
0.8%
(..-..)
150
OTOP
3/2550
+4.9 %
OTOP

(..51/...50)
50
(.. 50-..51)
184.53

-
33

-
14.58

- (..51)
11
( OTOP)
-
- (..51)
-
--
2550
-
50.91

(.. 50-..51)
224.60

-
33.16
2551 123.9 2550
-
160
122.3 1.3
-
1,673
2.3
(.. 50-..
11,675
14.8
51)

7
9

(..50-..51)
13

(..
14
( )
50-..51)
1

(..
+1.3 %
50-..51)

-

-
* 139.62
1.5

109

-
-
..51 (+ /
- ..50)
OTOP (..50)
-
- kiosk (..50)
OTOP ,
,

()
(
)
-
- (..51)
- (..51)
-

*202,500
2,220,807.61
1,259,648
961,159.61
298,488.39



0.6

3
3 2 2
1.5
1.0

2.
()
2551

,

1. 2550/51
1 .
(1996)
2. 2550/51

15 2551
()

11,500-12,500
10% ()
8,400-8,850
10% ()
7,800-8,000
BOI
BOI - - :

110

111

ROBINSON

...

.
.

24

112

113

30

.

( )




















Chain
-





28/3 . .
194/9 . .
119/121-123 . .
193 . .
478 . .7 . .
139-141 . .
90/27 . .
33/17 . .
. .
317/7 . .
90/8 . .
244/2 . .
90/5 . .
201-203 . .
7/34 . .
302/16 . .
103/1 .14 .
45 .3 .
23/6 . .
116/12 . .
65/1 . .
95/123 . .
7/5-6 . .
1 .
501/3 . .
228 . .
198/24 . .
178/5 . .
173/1 . .
3/5 . .
227/2 . .

114











.







.







.



.


306 . .11 .
392 . .
499/117 . .7 .
210/8 . .
374 . .
55/31-32 . .
96 .1 .
189/7 . .
78 . .
231/45 . .5 .
349 .14 . .
305/1 . .
53 . .
358 . .
296/41 . .
489/4 . .
13/24 . .
364 . .2 .
169/3-4 . .
47 . .
55/10 . .
83 . .
296 . .
90/3 . .
194 . .
49/7 . .
166/1-2 . .
1/20 . . .1 .
68/2 . .
48/1-2 . .
339/36 . .
282-283 . .
540/25 . .

115































.


( , 2551)

349 .
381 . .
52/4 . .
77/4 .1 . .
4/8-9 . .
36/16 . .
11/12-13 . .
97/2 . .
497/2 . .
49/10 . .
53 . .
2/18 . .
158/5 .1 .
69/22-23 . .
51 . .
23/3 . .
187/14 . .
183 . .
12/13 . .
497/24 . .
7/5 . .
197/1 . .
92 . .
260/2-3 . .
42/12 . .
2/2 . .
244/6 . .
169/8 . .
381 . .
5/11 . .
70 . .
188/7 . .

116

117

31

0001
_ 0001
_ 0001
_ 0001
_ 0001
_ 0001
_ 0001
_ 0001
_ 0001
_ 0001
_ 0001
_ 0001
0001
0001
0001

118


( )

119

32

0001
0002
0003
0004
0005
0006
0007
0008
0009
0010
0011
0012
0013
0014
0015
0016
0017

Ampicillim 250 mg.

0.40

678

Exp12/02/12

Bedexin

0.45

350

Exp 15/10/11

Bisacadyl ()

0 .50

566

Exp 25/04/13

Bisccodyl ()

0.50

896

Exp 16/01/11

Bromhex

0 .25

478

Exp 05/05/13

CARYOPIN

0 .45

689

Exp 09/11/12

CHLORPHENINE

0.45

957

Exp 14/07/12

Cyproheptadine HCI

0 .40

367

Exp 06/08/11

Dany

0 .50

967

Exp 18/09/12

Dextromethorphan HBr

0.50

578

Exp 15/12/12

Dextromethorphan HBr 15 mg.

0.75

789

Exp 17/06/13

Falete

0.75

456

Exp 25/11/12

FERLI - 6

0.25

890

Exp 18/12/11

FERROUS FUMARATE

0.50

698

Mf04/10/08

Furosic

0.25

649

Mf05/09/08

Gesica 400

0.50

965

Exp 11/12/13

Hyosman

0.10

456

Exp 26/10/12

120

33 :

_ 0001

Amexicillin 500

40

40

Exp 29/12/13

_ 0002

Bethasone 5g

25

21

Exp 15/09/12

_ 0003

Betnovate -N 5g

26

15

Exp 16/12/13

_ 0004

Coamox 250

36

17

Exp 04/06/11

_ 0005

Doxycycline 100 mg.

25

25

Exp 05/09/12

_ 0006

Grieofolvin 500 mg.

57

17

Exp 16/15/11

34 :

_ 0001

120cc

62

Exp 08/06/13

_ 0002

15cc

15

Exp 26/06/11

_ 0003

60cc

42

Exp 05/10/12

_ 0004

SARA

10

12

Exp 06/11/11

_ 0005

Tylinol

10

12

Exp 24/10/13

_ 0006

Cemol

20

Exp 29/05/13

35 :

_ 0001 Topicorte 15g.

40

10

Exp 05/10/12

_ 0002 TRAMODA

35

Exp 06/12/11

_ 0003 TYLENOI

40

11

Exp 15/06/12

_ 0004 (1 g.)

35

Exp 06/12/11

_ 0005

35

10

Exp 07/12/12

_ 0006 -

30

15

Exp 09/10/11

121

36 :

_ 0001 OPTIVIS 5 g

30

15

Exp 08/11/12

_ 0002 OSCIN

25

10

Exp 08/05/12

_ 0003 (120 cc.)

35

Exp 11/10/13

_ 0004 (350 cc.)

50

12

Exp 28/10/12

_ 0005

30

14

Exp 29/11/10

_ 0006

30

16

Exp 08/11/12

37 :

_ 0001

Vitamin B Complex

_ 0002

0.25

1000

Exp 08/11/12

Vitamin C 25 .

10

Exp 08/05/12

_ 0003

Vitamin C 60

10

10

Exp 11/10/13

_ 0004

Vitamin C +

10

Exp 28/10/12

_ 0005

Vitamin C 25 .

10

15

Exp 29/11/10

_ 0006

Vitamin C : 1

10

Exp 16/02/13

38 :


_ 0001
_ 0002
_ 0003
_ 0004
_ 0005
_ 0006

Carminative Mixtury 180ml

30

Coccila 30 ml.

30

Combizym

40

Daflon 500mg

20

DERMAZIN 25 g.

30

Disento

15

Exp 08/10/12
Exp 03/11/12
Exp 08/10/13
Exp 08/11/13
Exp 09/05/12
Exp 08/12/13

122

39 :

_ 0001

ANAMAI

100

Exp 16/09/13

_ 0002

Dior 21

130

10

Exp 18/11/12

_ 0003

Dior 28

130

12

Exp 09/05/11

_ 0004

EXLUTON

100

Exp 11/13/11

_ 0005

Meliane 21

110

Exp 07/09/12

_ 0006

Meliane 28

110

Exp 11/11/13

40 :

_ 0001

Bisolvon Pediatric

45

10

Exp 25/04/13

_ 0002

CHLOPHENIRAMINE

40

Exp 16/01/11

_ 0003

Chlorpheniramine SYRUP

55

Exp 05/05/13

_ 0004

CLARID

45

10

Exp 09/11/12

_ 0005

Clarityne

40

Exp 14/07/12

_ 0006

HYDROX 25 mg

30

Exp12/02/12

41 :

_ 0001

15

Exp 06/11/11

_ 0002

25

Exp 24/10/13

_ 0003

Flemex

60

Exp 29/05/13

_ 0004

Iyafin

38

Exp 27/10/12

_ 0005

30

Exp 08/06/12

_ 0006

40

Exp 05/06/12

123

42 :

_ 0001

45

Exp 14/07/12

_ 0002

(60 cc.)

28

Exp 14/11/13

_ 0003

60cc

55

Exp 11/13/11

_ 0004

(180 ml.)

20

Exp 05/08/13

_ 0005

(450 ml.)

35

Exp 15/09/12

_ 0006

( )

20

Exp 16/09/13

43 :

_ 0001

Boxing 15g

90

Exp 08/12/13

_ 0002

Caladryl 55 ml.

32

Exp 06/08/11

_ 0003

CA-R-BON

20

Exp 11/05/12

_ 0004

CHALKCAC

35

Exp 13/12/13

_ 0005

Comox

40

12

Exp 11/12/11

_ 0006

Hybutyl 30 ml.

25

10

Exp 08/10/13

124

44

0001

13

06/12/11

0002

Natural rubber

35

23

03/02/12

0003

Super grade

30

13

05/04/13

0004

20

23

Exp 29/04/13

0005

needle terumo

11

Exp 09/04/12

0006

Test Ckeck

63

14

Exp 09/11/13

0007

Test Orange

65

13

Exp 07/08/11

0008

Test Pres Color

58

15

Exp 08/12/13

0009

Test

55

Exp 29/04/13

0010

32

Exp 09/04/12

0011

1,2

15

14

Exp 15/11/13

0012

35

17

Exp 08/11/12

0013

30

19

Exp 29/04/13

0014


Nexcare
( 1/2 *1.5 )
Nexcare
( 1/2 *2.5 )
Nexcare
( 1/2 *5 )

55

Exp 09/04/12

33

Exp 15/11/13

25

Exp 16/02/13

26

Exp 15/12/13

0015
0016
0017

125

45

0001

C 1000 100

215

Exp 29/04/13

0002

Catherine 24g

85

Exp 09/04/12

0003

Chelavite plus 30

250

Exp 11/05/12

0004

Collagen Blink

21

Exp 13/12/13

0005

Dalacin Tim 10ml

25

Exp 06/08/11

0006

Everfame Chromilate 100

29

Exp 29/04/13

0007

Hi Srim 25.5 g 30

180

Exp 09/04/12

0008

K T D cod liver oil 100

159

Exp 09/11/13

0009

L.C.H Bioplus 30

310

Exp 07/08/11

0010

L.C.H Bioplus Anti - Cellulite

325

12

Exp 08/12/13

0011

Loprox 8ml

115

14

Exp 29/04/13

0012

Patap cod liver oil 100

218

Exp 29/04/13

0013

Peptide Collagen 100 110 g

235

Exp 09/04/12

0014

Seven seas 120 ml

26

Exp 11/05/12

0015

Viteen 30

215

Exp 29/04/13

0016

60

289

Exp 09/04/12

0017

60

299

Exp 09/11/13

126

46

0001

Acneaid Bar 50g

29

12

Exp 09/04/12

0002

Acneaid Liquid cleanser 100ml

45

13

Exp 11/05/12

0003

Aczee f gel 20g

35

15

Exp 13/12/13

0004

Amela Ex anti malasma cream

89

12

Exp 29/04/13

0005

Bosisto's

45

11

Exp 09/04/12

0006

Clinda M 10 ml

23

12

Exp 09/11/13

0007

Clinda M 100 ml

33

11

Exp 07/08/11

0008

Dentiste 50 g

45

Exp 09/11/13

0009

Exxe brightenning facial foam

59

Exp 07/08/11

0010

Exxe Serum 30ml

155

Exp 08/12/13

0011

Eye Q10 gel 10g

210

Exp 29/04/13

0012

Ferm hair remoring cream 40 g

69

Exp 05/08/12

0013

Hirudoid cream 14g

43

Exp 08/07/12

0014

Hirudoid cream 40g

65

12

Exp 29/04/13

0015

Hirudoid cream 5g

35

13

Exp 09/04/12

0016

Hirudoid forte 14 g

45

11

Exp 09/11/13

0017

Hirudoid forte 40 g

69

14

Exp 07/08/11

127

128




: 2

1 :

2 :
3 :
1 :

1.

18
19 25

26 - 30
30

2.

3.

/./.

4.
/

/
/
..........................................
5.
5,000
5,001 10,000

10,001 15,000
15,001

129

2 :
6. ( 1
2 3 )



()
()
()
()

7.

/
.........................................

8. ( 3 ;
1 , 2 3
)









..........................................
9.




...........................................
10. ( 1 )
(/ )
( )

11.
06.01 09.00 .
09.01 12.00 .

15.01 18.00 .
18.01 21.00 .

130

12.01 15.00 .
12.
()

21.01 24.00 .
()

3 :
13.

14.






.................................
15.
/
( )




................................................

131

132


( 1 2550)

1 .. 48
1. . / . .
4,880
5,080
2. . . 1
5,530
5,760
3. . / 2 . 2
6,220
6,470
4. . / 3 . 2
6,820
7,100
5. (4 ) . 3
7,630
7,940
6. (5 ) ( .. ) . 3
8,360
8,700
7. ( 4 + 2 ) . 4
9,320
9,700
8. . 4
9,790
10,190


9. 7 ( 5 + 2 ) . 4
10,250
10,660
10. . 5
12,600
13,110
( , www.ocsc.go.th :2551)

133

134

1 31 2550 2551
:
2550

2551

1,313,629.00
465,445.00
848,184.00

1,226,648.00
524,736.00
701,912.00

120,000.00
90,000.00
5,478.00
13,047.00
1,168.00
229,693.00
618,491.00
185,547.30
432,871.70

120,000.00
90,000.00
5,029.00
12,568.00
9,430.00
237,207.00
464,705.00
139,411.50
325,293.50

135

1 31 2550 2551
:
2550

2551

2,254,250.00
1,065,829.00
1,188,421.00

2,395,254.00
1,147,514.00
1,247,740.00

120,000.00
42,000.00
3,680.00
1,254.00
166,934.00
1,021,487.00
306,446.10
715,040.90

120,000.00
42,000.00
3,754.00
1,190.00
166,944.00
1,080,796.00
324,238.80
756,557.20

136

137

47 1 ..2550-2551
1 .. 2550 - 2551
1
2
3
4
325,420
343,900
319,651
342,658
314,059
294,386
297,634
320,569

..
2550
2551

1
14

13.44

13.5

13

13.39

12.72

12.5

12.53

12.49

12.28

12

2550-2551
11.63

11.51

11.5
11
10.5
1

25
1 ..2550-2551
47 25 1
..2550-2551 1
4 ..2550 2 ..2551 13.39% 11.53% 1.86%

138

48 2 ..2550-2551
2 .. 2550 -2551
1
2
3
4
553648
549,680
556,642
594,280
605,427
586,591
589,591
613,594

..
2550
2551

2
13.5
13

13.2

13.02
12.78

12.68

12.62

12.5

2550-2551
12

11.91

11.97

11.82

11.5
11
1

26
2 ..2550-2551
48 26 2
..2550-2551 2
2551 2 1 13.02% 12.62%
0.4%

139

140

49 1 ..2550-2551

%
..
() () () ()

2550 646,859
49.24
171,593
13.06
321,564
24.48
173,613
13.22
2551 652,136

53.17

148,644

12.12

269,546

21.97

156,322

12.74

1
60

50

49.24

53. 17

40
30

24. 48

20

..2550

21.97

..2551

13. 22 12. 74

13. 06 12. 12

10
0

27
1 ..2550-2551
49 27
1 ..2550-2551 ..2550 2.51%

141

50 2 ..2550-2551

..

()

%
() () ()

2550 1,226,534 50.64


169,497 49.45
583,596 55.65
334,623 45.68
2551 1,295,482 53.36

173,264

50.55

468,647 44.35

377,861 54.32

60

50.64

53.36

50

49.45 50.55

55.65

54.32
44.35

45.68

40
.. 2551

30

..2552

20
10
0

28
1 ..2550-2551
50 28
2 ..2550-2551 ..2550 11.3 %

142

143

1.
( 26)
( 28)
( 31)
2. /

( 26)
( 87)
(62)

2,000 10,000
20,000 100,000
20,000

2,000 10,000
20,000




( 1/2547 12
2547)
- (freeze) -20C -10C
- (cold store in refrigerator 2 8C)
- (cool place) 8-15C
- (controlled room temperature) 20-25C

-
-

144

- pilocarpine, chloramphenicol
- ()
- ergot
- ( 7 )

-
-
-
(in cool place)
15C

- Furosemide tab
- Carbidopa
- 1-6-12
-
- , , , ,

- Paraldehyde
4 ...
- 7
- 7
7
- beyond use date
30 14

6
...




, Expired Date,
Expiration Date, Exp., Used Before Mfg.,
3-5 2-3

145

1 /



beyond use date beyond use date

1 beyond use date
....







1.
1.1
1.2
1.3
1.4
10
2.
3.

- -
-

- ( Promotion Area )

1.
2.
3.
4.

146


1.
2.
3.
4.
5. Computer
6. Printer
7.
8.

147

148

149

(
)


( )
..2510

88, 89, 90

88, 90
124, 124



1.
2.

-
-
-
-
2
1. ( = ) /
xxxx / 254x
2. ( =, )
xxxx / 254x

150

1.
- : /

- : /
(, )
: / / /

2.
- 4 2

- 10-15
- 30
-+
-
( / )
-

151

152



(Product Service)
(Information Service)


" "

1





1.1
1.1.1

1.1.2

1.1.3
1.1.4

1.1.5
1.1.6

1.1.7
. ""
.

.
. " "
" " " "

153

1.2
1.2.1

-
-
-
-
-
1.2.2

1.2.3

1.2.4

1.2.5
.

.

1.3
1.3.1
1.3.2
1.3.3 ( )
2




2.1
2.1.1

154

.

.

.
.
2.1.2 ()
.
.
.
2.2
2.2.1
(standard practice guidelines)

2.2.2
2.2.3
2.2.4

2.2.5
.
.
2.2.6

2.2.7 (double check)

2.2.8


2.2.9

155

3.1


3.1.1
(GMP)
3.1.2

3.1.3
3.1.4

3.1.5

3.2
3.2.1

3.2.2
()

3.2.3
.
.

3.2.4
.
.

.

. 12

156


.
12
3.2.5 (patient's drug profile)

3.2.6

3.2.7
3.2.8
3.2.9

3.2.10
4

4.1
4.2 (laws and regulations)

4.3
4.4 1

4.5 (patient confidentiality)

4.6
4.7

157

5.1

5.2
5.3

5.4
5.5
5.6

158


13 2529
4

13 2528
4

16 2528
4